The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

The companies’ icotrokinra, or JNJ-2113, significantly cleared skin compared to placebo in patients with moderate to severe ...

If you have eczema you’ll be all too familiar with those cracked, dry, and scaly patches of skin that show up a bright red on ...

The following is a summary of “Identification of risk factors associated with metabolic dysfunction-associated steatotic liver disease in psoriatic patients,” published in the November 2024 issue of ...

Low patient satisfaction in psoriasis and psoriatic arthritis for clinicians and treatment is tied to need for better ...

Johnson & Johnson (J&J) has reported positive topline outcomes from its Phase III ICONIC-LEAD trial of oral icotrokinra ...

The once-daily pill, icotrokinra, was tested in patients with moderate-to-severe plaque psoriasis, a skin condition that ...

Vista, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, today announced a strategic partnership with the National Psoriasis ...

Nov. 12, 2024 — Researchers have developed a patch for easier and more effective treatment of psoriasis. The method may also be used in treatment of other ...

Researchers at the University of Copenhagen have developed a patch for easier and more effective treatment of psoriasis. The ...